Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Vitamin K2-containing pharmaceutical composition for improving cardiovascular calcification as well as preparation method and application thereof

A composition and vitamin technology, applied in the direction of drug combination, medical preparations containing active ingredients, cardiovascular system diseases, etc., can solve the problems such as the role of reversing calcification is not taken seriously, the biological activity is reduced, and intestinal absorption is difficult, etc. Achieve the effects of improving the body's immunity, improving vascular calcification, and avoiding body damage

Pending Publication Date: 2022-07-15
NANJING SHENGDE INST OF BIOTECHNOLOGY CO LTD +1
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Vitamin K present 2 It is generally used as a dietary supplement to promote calcium absorption, protect joint health, and strengthen bones. Its role in reversing calcification has not been valued or rarely used
Also due to vitamin K 2 It is a fat-soluble vitamin with low solubility in water, difficulty in intestinal absorption after oral administration, and low bioavailability
and vitamin K 2 Extremely sensitive to light and heat, the shelf life of conventional related products is unstable, and the biological activity is seriously reduced after long-term storage

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Vitamin K2-containing pharmaceutical composition for improving cardiovascular calcification as well as preparation method and application thereof
  • Vitamin K2-containing pharmaceutical composition for improving cardiovascular calcification as well as preparation method and application thereof
  • Vitamin K2-containing pharmaceutical composition for improving cardiovascular calcification as well as preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0084] This embodiment provides a kind of vitamin K containing 2 (MK-7) The pharmaceutical composition for improving cardiovascular calcification, in parts by weight, contains the following components by weight:

[0085] Vitamin K 2 (MK-7) 0.18 parts, omega-3 fatty acids 1200 parts, PQQ 10 parts, coenzyme Q 10 (CoQ 10 ) 200 servings, vitamin D 3 (VD 3 ) 5 parts, 250 parts of soft capsule skin, 100 parts of enteric coating powder, and 50 parts of auxiliary materials.

[0086] Its preparation method is as follows:

[0087] (1) Granulation: Under the condition of avoiding light, mix MK-7, PQQ and tableting auxiliary materials in equal proportions, adopt dry granulation, and control the particle size at 100 mesh to obtain granulated granules;

[0088] (2) tableting: the particles obtained in step (1) are made into bare chips with a specified weight of 0.2 g using a tableting machine;

[0089] (3) Coated tablets: the bare tablets prepared in step (2) are mixed with enteric c...

Embodiment 2

[0094] The present embodiment provides a pharmaceutical composition containing vitamin K2 (MK-7) for improving cardiovascular calcification, which, in parts by weight, contains the following components by weight:

[0095] Vitamin K 2 (MK-7) 0.09 parts, 600 parts of omega-3 fatty acids, 10 parts of PQQ, coenzyme Q 10 (CoQ 10 ) 100 servings, vitamin D 3 (VD 3 ) 2 parts, 150 parts of soft capsule skin, 80 parts of enteric coating powder, and 30 parts of auxiliary materials.

[0096] Its preparation method is as follows:

[0097] (1) Granulation: Under the condition of avoiding light, mix MK-7, PQQ and tableting auxiliary materials in equal proportions, adopt dry granulation, and control the particle size at 120 mesh to obtain granulated granules;

[0098] (2) Tabletting: the particles obtained in step (1) are made into bare chips with a specified weight of 0.15g using a tablet press;

[0099] (3) Coated tablets: the bare tablets prepared in step (2) are mixed with enteric c...

Embodiment 3

[0104] This embodiment provides a kind of vitamin K containing 2 (MK-7) The pharmaceutical composition for improving cardiovascular calcification, in parts by weight, contains the following components by weight:

[0105] Vitamin K 2 (MK-7) 0.12 parts, 900 parts of omega-3 fatty acids, 15 parts of PQQ, coenzyme Q 10 (CoQ 10 ) 150 servings, vitamin D 3 (VD 3 ) 3 parts, 180 parts of soft capsule skin, 70 parts of enteric coating powder, and 40 parts of auxiliary materials.

[0106] Its preparation method is as follows:

[0107] (1) Granulation: Under the condition of avoiding light, mix MK-7, PQQ and tableting auxiliary materials in equal proportions, and use dry granulation, and the particle size is controlled at 80 mesh to obtain granulated particles;

[0108] (2) tableting: the particles obtained in step (1) are made into bare chips with a specified weight of 0.25 g using a tableting machine;

[0109] (3) Coated tablets: the bare tablets prepared in step (2) are mixed w...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a pharmaceutical composition containing vitamin K2 for improving cardiovascular calcification, which is composed of a composition I, a composition II and a composition III in a mass ratio of (0.1-5): (0.01-0.5): (100-500). The invention also provides a preparation method and application of the pharmaceutical composition. The pharmaceutical composition can comprehensively prevent and block cardiovascular calcification, is especially suitable for reversing cardiovascular calcification symptoms caused by taking statins, and provides a daily support and protection effect for heart health at the same time. The pharmaceutical composition disclosed by the invention has the advantages of stable active ingredients, high bioavailability, strong targeting property and no side effect, and can achieve the purposes of prevention and treatment at the same time.

Description

technical field [0001] The invention relates to the technical fields of medicine, health care products and food, in particular to a kind of vitamin K containing 2 A pharmaceutical composition for improving cardiovascular calcification and a preparation method and application thereof. Background technique [0002] Vascular calcification refers to the inappropriate biological calcification that occurs in the soft tissue of the cardiovascular system, and is a pathological change in which calcium salts are deposited in the arterial wall tissue. It is prevalent in various diseases such as atherosclerosis, diabetes, kidney disease, aging, and systolic hypertension, which can easily lead to myocardial infarction and cerebral apoplexy. Previous studies believed that vascular calcification is a passive, degenerative, and inevitable terminal process, but recent clinical and basic research results show that vascular calcification is similar to the process of bone development and carti...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/593A61K9/50A61K45/06A61K31/122A23L33/10A23L33/12A23L33/125A23L33/155A23L33/18A23P10/30A61P9/10A61P9/00A61P37/04A61P39/06A61P35/00A61P19/08A61K31/202A61K31/4745
CPCA23L33/10A23L33/155A23L33/125A23L33/18A23L33/12A61K31/122A61K31/4745A61K31/202A61K31/593A61K9/5084A61K45/06A61P9/10A61P9/00A61P37/04A61P39/06A61P35/00A61P19/08A23P10/30A23V2002/00A23V2200/326A23V2250/7144A23V2250/612A23V2250/702A23V2250/314A23V2250/21A23V2250/211A23V2250/21168A23V2250/2116A61K2300/00
Inventor 何天明史鲁秋薛虹宇苏桂珍
Owner NANJING SHENGDE INST OF BIOTECHNOLOGY CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com